NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
“With cancer cases on the rise, we’ve seen tremendous growth in FDA-approved targeted therapies and immunotherapies, making proper test selection critical for precision medicine-based patient management,” said
Recognizing the benefits of concurrent testing, as supported by the National Comprehensive Cancer Network (NCCN) guidelines, NeoGenomics’ comprehensive lung offering allows for complementary tissue and liquid biopsy testing. The test portfolio provides a comprehensive approach to diagnosis, therapy selection, prognosis, and clinical trial options tailored to each patient's unique needs, addressing the disease’s complexities:
- Early Stage NSCLC is the industry's first therapy selection panel for early-stage non-small cell lung cancer (NSCLC), delivering actionable insights within seven days.
- DNA & RNA Lung is a 50-gene NGS panel enriched with MSI and TMB analysis to facilitate precise therapy selection and clinical trial matching.
- InvisionFirst® Lung is a liquid biopsy assay that detects 37 genes crucial to NSCLC treatment. It surpasses tissue-based assays in actionable alterations and is available for patients without viable tissue samples.
- Comprehensive™ Solid Tumor test analyzes 517 genes via DNA and RNA next-generation sequencing, providing clinicians with a complementary understanding of the patient's cancer profile to guide optimal treatment options.
In addition to highlighting these solutions,
About
Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528418788/en/
Investor Contact
kendra.sweeney@neogenomics.com
Media Contact
asampson@sampsonprgroup.com
Source: